A Phase 1/2 interventional study of AOC 1020 and Placebo in FSHD, FSHD1 and FSHD2, sponsored by Avidity Biosciences, Inc.. Completed at 17 sites in 3 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Avidity Biosciences, Inc. (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.
Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 5th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 in phase 1/2, and was the 22nd registered.
79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.
Browse Muscular Dystrophy, Facioscapulohumeral studies →8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:
Scholar Rock, Inc. · Sites in United States
Ages 18–60
Restem, LLC. · Sites in United States
Ages 15+
Jeffrey Statland · Sites in United States
Ages 18–75
Avidity Biosciences, Inc. · Sites in United States, Canada, Denmark and 7 more countries
Ages 16–70
University of Kansas Medical Center · Sites in United States, Australia
Ages 5–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 15 · Phase 3 2
First in 2000; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 48 across 49 interventional studies indexed under Muscular Dystrophy, Facioscapulohumeral.
Median enrollment 51 across the 21 interventional studies, 94 across the 11 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Avidity Biosciences, Inc., one of the names counted as Novartis. Under that name alone:
Avidity Biosciences, Inc. is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Novartis has 3 studies filed under Muscular Dystrophy, Facioscapulohumeral — fewer than ten, so there is no comparison to draw.
3 of the studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06847282University of Kansas Medical CenterMotor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) | 2027-05 |
| NCT05019625Massachusetts General HospitalBiomarker Development for Muscular Dystrophies | 2027-06 |
| NCT06907875Epicrispr Biotechnologies, Inc.A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | 2027-07-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
AOC 1020-CS1 is a first-in-human, 3-part, multi-center, Phase 1/2, randomized, double-blind, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics and to explore pharmacodynamics and efficacy of single and multiple-doses of AOC 1020 administered intravenously in participants with FSHD Type 1 (FSHD1) and FSHD Type 2 (FSHD2).
Cohort A comprises a placebo-controlled dose titration cohort (Cohort A1) which includes a nested single and multiple dose schedule. Cohort B comprises a placebo-controlled, nested single ascending dose (SAD)/multiple ascending dose (MAD) cohort (Cohort B1). Cohort C comprises a randomized, placebo-controlled, expansion cohort (Cohort C1). For each of Cohorts A, B, and C the study duration is 12 months as the active treatment period is approximately 9 months for Cohorts A \& B and approximately 10.5 months for Cohort C followed by a 12-week follow-up period for Cohorts A \& B and a 7-week follow-up period for Cohort C. Once participants have completed active treatment with follow-up through 12 months, they may have the option to participate in a planned open-label extension. If patients do not immediately roll over into the open-label extension study or decline participation, they will be followed for 18 weeks after their last dose of study medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months
Drug: AOC 1020
Cohort B1: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months
Drug: AOC 1020
Cohort C: AOC 1020 Dose Regimen 3; Eight doses administered intravenously over approximately 10 months
Drug: AOC 1020
Cohort A \& B: Placebo; Five doses administered intravenously over 9 months
Drug: Placebo
Cohort C: Placebo; Eight doses administered intravenously over approximately 10 months
Drug: Placebo
AOC 1020 will be administered via intravenous (IV) infusion
Placebo will be administered via intravenous (IV) infusion
Also known as: Saline
Incidence of treatment-emergent adverse events (Cohorts A & B)
Time frame: Through study completion, up to Day 365
Change in plasma KHDC1L (Part C)
Ratio to Baseline
Time frame: Across months 3 to 12
Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)
Observed maximum concentration
Time frame: Through study completion; up to Day 365
Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)
Observed half-life
Time frame: Through study completion; up to Day 365
Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)
Observed area under the curve
Time frame: Through study completion; up to Day 365
Muscle drug concentration (Cohorts A & B)
Concentration of siRNA component in skeletal muscle
Time frame: Day 120
Change in circulating creatine kinase (Cohort C)
Ratio to Baseline
Time frame: Across months 3 to 12
Plan to share: No
Ran from Apr 2023 to primary completion in Mar 2026, 35 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AOC 1020
Muscular Dystrophy, Facioscapulohumeral →